Stem Cells for Myocardial Repair With Use of a Transarterial Catheter

Xiaohong Wang, MD, PhD; Mohammad Nurulqadr Jameel, MD; Qinglu Li, BS; Abdul Mansoor, MD, PhD; Xiong Qiang, MS; Cory Swingen, PhD; Carmelo Panetta, MD; Jianyi Zhang, MD, PhD

Background—Using a swine model of postinfarction left ventricle (LV) remodeling, we investigated marrow-derived, multipotent progenitor cell (MPC) transplantation into hearts with acute myocardial infarction (AMI) via a novel transarterial catheter.

Methods and Results—The left anterior descending coronary artery was balloon-occluded after percutaneous transluminal angiography to generate AMI (60-minute no-flow ischemia). The transarterial catheter was then placed in the same coronary artery, and either 50×10⁶ MPCs (cell group, n=6) or saline (control, n=6) was injected into the border zone (BZ) myocardium. LV function was assessed by magnetic resonance imaging before AMI and at 1 and 4 weeks after AMI, whereas myocardial energy metabolism was assessed by ³¹P-magnetic resonance spectroscopy at week 4. One week after AMI, the ejection fraction was significantly reduced in both groups from a baseline of 50% to 31.3±3.9% (cell group) and 33.3±3.1% (control). However, at week 4, the cell group had a significant recovery in ejection fraction. The functional improvements were accompanied by a significant improvement in myocardial bioenergetics. Histologic data demonstrated a 0.55% cell engraftment rate 4 weeks after MPC transplantation. Only 2% of engrafted cells were containing positive for cardiogenic markers. Vascular density in the BZ was increased in the cell group. Conditioned medium from cultured MPCs contained high levels of vascular endothelial growth factor, which was increased in response to hypoxia. MPCs cocultured with cardiomyocytes inhibited changes in cardiomyocyte mitochondrial membrane potential and cytochrome c release induced by tumor necrosis factor-α.

Conclusions—Thus, a paracrine effect may contribute significantly to the observed therapeutic effects of MPC transplantation. (Circulation. 2009;120[suppl 1]:S238–S246.)

Key Words: stem cells ■ metabolism ■ myocardial infarct

Stem cell transplantation has emerged as a novel therapeutic strategy for limiting postinfarction left ventricular (LV) remodeling and the consequent development of congestive heart failure in both animal1–4 and clinical5–9 studies. Using a swine model of post–myocardial infarction (MI) LV remodeling, we recently reported that transplantation of bone marrow–derived, multipotent progenitor cells (MPCs) resulted in a significant improvement of cardiac function and correction of abnormal energy metabolism.1 However, the mechanisms underlying these beneficial effects are not well defined. We and others have demonstrated a very low engraftment rate and an even lower cardiomyocyte differentiation rate a few weeks after bone marrow stem cell transplantation.1,10 Therefore, the direct contribution of regenerated myocytes to the improved cardiac contractile function appears less likely. The group of Dzau and colleagues10–12 has shown a significant protection of stressed cardiomyocytes from apoptosis and a consequent reduction in infarct size by injection of concentrated cell culture medium that was obtained from bone marrow–derived mesenchymal stem cells (MSCs) with overexpression of Akt, or by injection of MSCs themselves into the myocardium at the time of acute MI. More recently, they demonstrated that the frizzled related protein 2 is the key paracrine factor secreted by Akt-modified MSCs that mediates myocardial survival and repair.13 Using a swine model of concentric LV hypertrophy (LVH), we have demonstrated that transplantation of vascular endothelial growth factor (VEGF)–overexpressing MSCs at the time of ascending aortic banding markedly attenuated the development of LVH and resulted in the preservation of LV contractile performance and bioenergetic characteristics,14 supporting the notion that the beneficial effects after bone marrow stem cell transplantation are mediated through a paracrine mechanism by secretion of trophic factors from stem cells that exert a protective effect.
Many different approaches have been used to deliver stem cells into the heart, including direct intramyocardial, intravenous, intracoronary, and retrograde coronary venous routes. Intracoronary infusion of stem cells at the time of angiography seems the most practical approach clinically. However, its efficacy and safety remain an issue. In a canine model, it was reported that coronary artery infusion of stem cells resulted in blockage of small vessels, which in turn caused discrete micromyocardial necrosis. The Microsyringe infusion catheter (Mercator MedSystems) used in the present study has the unique feature of a microneedle that penetrates the coronary artery wall and allows the user to inject the stem cells directly into the myocardium.

The present study had a 2-fold hypothesis. First, we hypothesized that MPC delivery via the Micro-syringe infusion catheter would be safe and effective in a clinically relevant porcine model of myocardial ischemia/reperfusion. Second, we hypothesized that a trophic effect plays an important role in mediating the myocardial structural changes that lead to the beneficial effects of cellular therapy. Namely, the engrafted cells release cytokines that result in enhanced angiogenesis, maintenance of mitochondrial integrity, and inhibition of apoptosis of ischemia-threatened and over-stretched myocytes in the border zone (BZ) myocardium adjacent to the myocardial infarct. These structural changes are accompanied by an improvement of BZ myocardial contractile performance, which in turn results in ameliorating the LV wall stress and myocardial bioenergetics.

Methods

All experiments were performed in accordance with the animal use guidelines of the University of Minnesota, and the experimental protocol was approved by the University of Minnesota research animal resources committee. The investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH publication No. 85-23, revised 1985).

Cell Culture

MPCs were provided by Athysis, Inc, which were derived from 1 of the male swine multipotent adult progenitor cell lines generated at the University of Minnesota. MPC isolation, expansion, and differentiation were performed as described previously and are described in detail in the online-only data supplement.

Myocardial Ischemia/Reperfusion Model and Transarterial Stem Cell Injection

Young Yorkshire female swine (~20 kg; Manthei Hog Farm, Elk River, Minn) were anesthetized with pentobarbital (30 mg/kg IV), intubated, and ventilated with a respirator with supplemental O2. Left heart catheterization was performed. MI was created by balloon occlusion of the left anterior descending coronary artery (LAD) distal to the second diagonal for 60 minutes followed by reperfusion after anticoagulation. The transarterial catheter (Microsyringe infusion catheter from Mercator MedSystems) was then placed in the same coronary artery, and either stem cells (5 × 10^6/mL; n = 6) or saline (n = 6) was injected. The intramyocardial position of the needle was confirmed under fluoroscopy in the cardiac catheterization laboratory with contrast diluted for both placebo and cell injection to confirm delivery outside the vessel lumen. Five equal injections for a total of 50 × 10^6 MPCs were given, with a final volume of 1 mL. When ventricular fibrillation occurred, electric defibrillation was performed immediately. Animals received standard postoperative care, including analgesia, until they ate normally and became active.

MRT Methods

Animals were examined at baseline, 1 week after MI, and then 4 weeks after MI by magnetic resonance imaging (MRI). MRI was performed on a 1.5-T clinical scanner (Siemens Sonata, Siemens Medical Systems, Islen, NJ) with a phased-array 4-channel surface coil and ECG gating. Details of the MRI methods are described in the data supplement.

1H-NMR Spectroscopy and Spatially Localized 31P-NMR Spectroscopy Technique

Animals were returned to the laboratory for a final open-chest MR spectroscopic study 4 weeks after MI. The 1H-nuclear (N) MR and 31P-NMR spectroscopy techniques are described in detail in the data supplement.

Surgical Preparation for Open-Chest MR Spectroscopy Study

Detailed surgical preparations for the MR spectroscopy study have been published previously and are described in the data supplement.

MR Spectroscopy Study Protocol and Hemodynamic Measurements

Hemodynamic measurements were acquired simultaneously with the NMR spectra. Aortic and LV pressures were measured with pressure transducers positioned at midchest level and recorded on an 8-channel recorder. After all of the baseline data were obtained, animals received a combined dobutamine and dopamine infusion (20 μg/kg per min each) to induce a very high cardiac work state. After an ~5-minute wait after the initiation of catecholamine infusion, all of the spectroscopic and hemodynamic data were again measured under the high cardiac work state.

Tissue Preparation

The LV was sectioned in a bread-loaf manner into 6 transverse sections (~10 mm in thickness) from apex to base. Even rings were subdivided into 12 circumferential specimens and fixed in zinc fixative (Anatech Ltd, Battle Creek, Mich) for hematoxylin and eosin staining, immunofluorescence staining, and engraftment evaluation.

Engraftment Evaluation

Each of the 12 pieces of cardiac tissue of a short-axis ring was stained with X-gal (Invitrogen) and embedded in Tissue-Tek OCT (Fisher Scientific). Serial cryostat sections (10 μm in thickness) were obtained from the whole transverse ring and then multiplying by 10 to obtain the total number of engrafted MPCs per ring. The total number of engrafted MPCs equals 2-fold the number of X-gal–positive staining cells in all 3 even rings. The engraftment rate of transplanted MPCs was calculated by dividing the total number of engrafted MPCs by 50 × 10^6 (the number of MPCs injected) and multiplying by 100%.

Immunohistochemistry

Detailed immunohistochemistry methods have been described previously. In brief, cryostat sections (10-μm thickness) were obtained for immunofluorescence staining to evaluate myocyte or endothelial differentiation of injected cells. Antibodies used included troponin T (cardiac isoform Ab-1; Laboratory Vision Corp, Chicago, Ill) and α-sarcomeric actin, N-cadherin, and CD31 (Research Diagnostic, Inc, Flanders, NJ). Nuclear counterstaining was performed with 4′,6′-diamino-2-phenylindole (DAPI, Molecular Probes, Grand Island, NY).
by guest on April 14, 2017 http://circ.ahajournals.org/ Downloaded from

and insulin-like growth factor (IGF) content according to the
unconcentrated supernatants were subjected to ELISA for VEGF

...group was cultured under normoxic conditions. Eighteen hours later,

...and Cytochrome c Release

MPCs Cocultured With Neonatal Cardiomyocytes and Cytochrome c Release

Primary cultures of cardiac myocytes were prepared by enzymatic
digestion of ventricles obtained from neonatal (2-day-old) Sprague-
Dawley rats as previously described. Coculture experiments were
established in the fibronectin-coated chamber slides at a total density of
2×10^5 (1:1 ratio of cardiomyocytes to MPCs) in MPC medium supplemented
with 2% fetal bovine serum, 100 μg/mL penicillin, and 250 μg/mL streptomycin at 37°C in humid air with 5% CO2.
Cytochrome c release was detected by immunofluorescence staining
with an anti–cytochrome c antibody after cardiomyocytes and the
coculture cells were treated with 40 ng TNF-α. Troponin T was used
to stain cardiomyocytes. Double-staining cardiomyocytes were
detected and counted.

Statistics and Data Analysis

Anatomic data, wall stress data, capillary density, and the in vitro
apoptosis data were compared between the 2 groups (MI and MI+
cells) with Student’s t test. A repeated-measures ANOVA was
applied to compare the measurements of systolic thickening fraction,
ejection fraction (EF), and scar size across the 2 treatment groups
(MI and MI+ cells) and different time points (before MI and 1 and
4 weeks after MI) and to compare the measurement of myocardial
phosphocreatine (PCr)/ATP and hemodynamic data across the 2
treatment groups (MI and MI+ cells) and 2 hemodynamic conditions
(baseline and after inotropic stimulation). For comparison between
the 2 treatment groups, the conventional significance level of a type
1 error (P<0.05) was used. The Bonferroni correction for signifi-
cance level was used to take into account multiple comparisons. All
values are expressed as mean±SD. All statistical analyses were
performed in Sigmastat version 3.5 (San Jose, Calif).

Statement of Responsibility

The authors had full access to the data and take responsibility for its
integrity. All authors have read and agree to the manuscript as
written.
Results

Anatomic and Hemodynamic Data
Four of the 16 pigs with LAD occlusion and reperfusion died within the first 60 minutes after coronary occlusion due to ventricular fibrillation. The surviving 12 pigs were randomized to receive either MPCs (n=6) or saline only (n=6). The anatomic data for the 12 swine with LAD ligation is summarized in supplemental Table I. The degree of LVH as reflected by LV weight/body weight and right ventricle weight/body weight was not significantly different between the MPC and saline groups. The hemodynamic data at baseline and at increased workload are summarized in supplemental Table II. Inotropic stimulation caused a significant increase in heart rate and LV systolic pressure and consequently, the rate-pressure product. However, there was no significant difference between the swine with cell treatment and those without cell treatment.

Global Functional Data
The temporal changes in global function as measured by MRI are depicted in Figure 1. There was no significant difference between the 2 groups at baseline. At week 1, the distal LAD occlusion caused a similar scar size in both groups, with a significant decrease in LVEF, with no significant difference between the 2 groups. However, there was remarkable LV chamber functional recovery from 1 week to 4 weeks after cell transplantation (EF, 46.3±6.6% versus 33.3±3.1%, P<0.001), which was not observed in the control group (Figure 1A). Thus, at week 4, LVEF was significantly higher in cell-treated animals than in control animals (46.3±6.6% versus 35.4±3.2%, P<0.001; Figure 1A). This functional improvement in the MPC treatment group was accompanied by a significant decrease in scar size at 4 weeks compared with the saline group (4.8±1.9% versus 8.8±2.1%, P=0.047). It should be noted that there was a significant decrease in scar size from week 1 to week 4 in the cell-treated group (4.8±1.9% at 4 weeks versus 9.2±3.5% at 1 week, P<0.001; Figure 1B).

Regional Contractile Functional Data
The LV was divided into 16 segments. The apex was divided into 4, the mid-LV into 6, and the base into 6 segments. Distal LAD occlusion resulted in a thin-walled infarct in the apex, mainly in the anteroseptal segments (segments 1 and 2). The remaining apical segments (segments 3 and 4) are the BZ, and the mid-LV and base make up the remote zone. Systolic thickening fraction was measured as a surrogate marker of regional LV contractile function. Distal LAD occlusion alone resulted in systolic bulging of the infarct zone at 1 week, which persisted to 4 weeks (Table). MPC treatment resulted in an increased systolic thickening fraction of the infarct and BZ at 4 weeks compared with control (Table). Moreover, the systolic thickening fraction in the infarct and BZ within cell-treated animals was significantly increased at 4 weeks compared with 1 week (Table). LV wall stress (σ) in different LV segments at 4 weeks was calculated according to the Laplace law, as previously described, from the following equation: $\sigma = P R / (2 T)^{23}$, where $P$ is LV pressure, $R$ is chamber radius, and $T$ is wall thickness measured from cine MRI images in the particular region of the LV. MPC treatment resulted in a significant decrease in wall stress in the infarct (300±16 mm Hg in control versus 208±20 mm Hg in MPC-treated animals, $P=0.009$) and BZ (242±18 mm Hg in control versus 174±14 mm Hg in MPC-treated animals, $P=0.01$).

Myocardial High-Energy Phosphate and Inorganic Phosphate Levels
Myocardial high-energy phosphate and inorganic phosphate levels are reflected by the PCR-ATP ratios as shown in Figure 2. The PCR-ATP ratio was significantly higher at 4 weeks in the pigs treated with MPCs compared with those without such treatment (2.03±0.31 versus 1.53±0.28, $P=0.009$). After increased workload, the PCR-ATP ratio decreased in both groups but was still significantly higher in the cell-treated pigs (1.80±0.24 versus 1.43±0.25, $P=0.027$). No deoxy-
myoglobin resonance peak was detected in either group by 1H-NMR spectroscopy, which supports our previous finding that the BZ bioenergetic abnormalities in hearts with post-infarction LV remodeling are not caused by persistent myocardial ischemia.

Cell Engraftment and Differentiation In Vivo
Cell engraftment was determined by counting β-galactosidase-staining positive cells in tissue sections, and the cell engraftment rate was calculated as a percentage of engrafted cells from the total $5 	imes 10^6$ injected stem cells. Two additional pigs were euthanized at 10 days after MI and cell transplantation to assess engraftment at an earlier time. Ten days after cell transplantation, the cell engraftment rate was $\approx 5\%$. Most of the cells were retained in the infarcted area, and only a small portion of the engrafted cells resided in the peri-infarct and remote areas (Figure 3A). Four weeks after cell transplantation, the cell engraftment rate was remarkably decreased and reached 0.55% ($n=6$). To determine the differentiation of engrafted cells, tissue sections were double-stained for β-galactosidase and cardiac-specific markers, including troponin T, α-sarcomeric actin, and N-cadherin.

We found that $\approx 2\%$ of engrafted cells costained positive for β-galactosidase and troponin T or α-sarcomeric actin 10 days after cell transplantation (Figures 3B and 3C). These double-staining positive cells were only observed in the peri-infarct and remote areas. Among the cells that costained positive for β-galactosidase or α-sarcomeric actin, we identified gap junctions between the cells, as indicated by N-cadherin immunofluorescence staining (Figure 3B). These data suggest that transplanted MPCs engraft successfully and can undergo in vivo transdifferentiation into cardiomyocyte-like cells or form fused cells.

Vascular Density
To determine the mechanisms underlying the beneficial effects of MPC transplantation, we investigated the effects of MPC transplantation on neovascularization and angiogenesis in the post-MI hearts. At 4 weeks after cell transplantation, immunofluorescence staining for CD31 antibody indicated significant angiogenesis in stem cell–treated hearts, with more CD31-expressing capillaries being present in peri-infarct regions of cell-treated compared with saline-treated hearts (Figure 4A). Quantitative evaluation of CD31-positive
capillary numbers per high-power field (20×) indicated that vascular density was significantly greater in the MPC-treated group than in the saline-treated group (Figures 4A and 4B). However, few cells stained positive for both the endothelial cell marker CD31 and β-galactosidase (data not shown). These data suggest that transplanted MPCs may promote angiogenesis through a paracrine effect.

To further identify the angiogenic factors, we determined the levels of VEGF and IGF in the conditioned medium under different culture conditions. We found that MPCs can secrete detectable VEGF under normoxic condition, which was significantly increased in response to hypoxia (normoxia, 456.1±104.1 pg/5×10⁴ cells; hypoxia, 1543.8±77.1 pg/5×10⁴ cells, n=5, P<0.001). However, the IGF levels secreted under both conditions were too low to be detected. These data suggest that MPCs secrete VEGF, which is an important angiogenic factor contributing to the observed cellular therapy–associated beneficial effects.

Protective Effect of MPCs on Mitochondrial Membrane Potential
To investigate the protective effect of MPCs on cardiomyocytes, HL-1 myocyte apoptosis was induced by inflammatory factor TNF-α. Coculture of HL-1 cells with MPCs significantly inhibited TNF-α–induced apoptosis (HL-1+TNF-α, 32±3%; TNF-α+coculture, 14±1%, n=6, P<0.001; Figure 5A). To further determine its underlying mechanisms, the alteration in mitochondrial inner-membrane electrochemical potential was determined by staining with the cationic, lipophilic dye, JC-1. MPCs significantly inhibited TNF-α–induced HL-1 cell mitochondrial membrane potential changes (Figure 5B). Cocultured MPCs with neonatal cardiomyocytes also inhibited TNF-α–induced cytochrome c release from neonatal cardiomyocytes (Figure 5C). These data suggest that the paracrine factors secreted by MPCs play a protective role in preventing myocytes from apoptosis.

Discussion
The present study demonstrates that MPC transplantation through a transcoronary arterial catheter approach is safe, feasible, and effective. MPC transplantation is associated with increase in vascular density, inhibition of apoptosis, and reduction of infarct size, which is accompanied by improvement in BZ and infarct zone contractile function and consequent improvement in myocardial bioenergetics and global LV function. These functional beneficial effects were observed despite low engraftment of MPCs at 4 weeks. In vitro, the MPCs significantly inhibited TNF-α–induced mitochondrial membrane potential changes and cytochrome c release from myocytes. Additionally, coculture of MPCs with HL-1 cells inhibited TNF-α–induced apoptosis. Thus, the MPC–induced trophic effect results in structural changes that are characterized by increased vascular density, spared myocytes from apoptosis, and decreased infarct size, which in turn lead to an improvement of BZ myocardial contractile performance, amelioration of regional wall stress, and myocardial bioenergetics.
Stem Cell Delivery Via Transarterial Injection

Although clinical trials of intracoronary artery infusion of stem cells have shown moderate LV functional improvement,5,7–9 a report of a dog study suggested that coronary artery infusion of stem cells resulted in blockage of small vessels, which in turn caused discrete micromyocardial necrosis.16 In the present study, we used a transarterial catheter with a microneedle that penetrates the coronary artery wall and injects stem cells directly into the myocardium that is exposed to ischemia/reperfusion. We found similar engraftment of stem cells as in previous studies of open-heart direct intramyocardial injection.1,24 These data demonstrate that transcoronary injection of MPCs through this technique is safe and leads to an improvement in LV function.

Contractile Performance in the Infarct BZ

Increased LV wall stress in the BZ has been implicated among the factors contributing to LV remodeling after MI.18,25 It has been shown in a porcine model that MI leads to dyskinesia in the infarct region and hypokinesis in the infarct BZ.18 MPC transplantation caused an improvement in infarct and BZ systolic thickening fraction in the present study (Table), which in turn effectively reduced wall stress (BZ wall stress was 242±18 mm Hg in control versus 174±14 mm Hg in MPC-treated animals, \(P=0.01\)) and consequently improved the mismatch of energy delivery and demand (Figure 2).1,24 The contractile performance improvement in the BZ is likely based on the myocardial structural improvements that are characterized by increased vascular density (Figure 4) and reduced apoptosis (Figure 5) in the BZ and myocyte differentiation (Figure 3).

BZ Myocardial Energetics

Postinfarction LV remodeling is associated with decreased high-energy phosphates, PCr-ATP ratio, and expression of several proteins crucial to oxidative ATP production, and these abnormalities are most severe in the BZ.18 Our study confirmed these reports and showed that these abnormalities are worsened during a catecholamine stimulation–induced high cardiac work state (Figure 2). The improved myocardial bioenergetics in response to stem cell transplantation was also supported by the in vitro experiments indicating that mitochondrial inner-membrane electrochemical potential was significantly improved (Figure 5B), which could effectively increase the mitochondrial oxidative phosphorylation potential. This improvement in mitochondrial function may have an important role in cell survival and inhibition of the apoptotic pathway in resident cardiac progenitors.

Effect of Cell Transplantation on Infarct Size

Sequential MRI functional assessment allowed us to conclude that the infarct size in swine treated with MPCs decreased from week 1 to week 4, whereas scar sizes in swine without MPC treatment were maintained throughout follow-up (Figure 1B). This reduction in scar size with stem cell treatment has been noted in other reports.2–12 The beneficial effects of MPC transplantation could be related to MPC differentiation into cardiomyocytes26 or mobilization of endogenous progenitors to the injury site by paracrine effects.12 Recently, it has been shown that endogenous cardiac progenitor cells, on activation, can home to the infarcted myocardium and help in myocardial regeneration.27–30 In the present study, <1% of transplanted MPCs were engrafted at 4 weeks, and even a smaller percentage expressed markers of cardiomyocytes. This suggests that the functional and bioenergetic improvements are likely secondary to paracrine effects. The data from the present study indicate a trophic effect; ie, the cytokines released from the engrafted stem cells act on the host myocytes and spare them from apoptosis.

**Figure 5.** The protective effect of MPCs on cardiomyocytes. A, Cocultured swine MPCs and HL-1 cells significantly inhibited TNF-\(\alpha\)-induced HL-1 cell apoptosis (n=6, \(P<0.001\)). Data are mean±SD. B, Swine MPCs cocultured with HL-1 cells significantly inhibited TNF-\(\alpha\)-induced mitochondrial membrane potential changes. C, Swine MPCs cocultured with rat neonatal cardiomyocytes significantly inhibited TNF-\(\alpha\)-induced cytochrome c release.
Stem Cell–Induced Antiapoptosis Effect

Apoptosis does occur in failing hearts. Mitochondrial release of cytochrome c has been implicated in apoptosis induced by TNF-α. MSC transplantation has been shown to have significant antiapoptosis effects. Data from the present study support this hypothesis and further elucidate this finding by showing that MPCs co-cultured with neonatal rat cardiomyocytes inhibit TNF-α–induced cytochrome c release. Mitochondria play a central role in apoptotic pathways. It has been shown that the mitochondrial respiratory chain complex I is inhibited in the early phase of TNF-α–induced apoptosis. Inhibition of complex I can affect electron flow through the other complexes of mitochondrial oxidative phosphorylation leading to cytochrome c release and caspase-3 activation, followed by a reduction of mitochondrial membrane potential. The data from the present study demonstrate that the TNF-α–induced loss of mitochondrial membrane potential can be inhibited by stem cell treatment. The improvement in myocardial energetics in vivo with MPC treatment observed in the present study indicates that the impairment in the mitochondrial respiratory chain, FOF1 ATP synthase, and ATP production is ameliorated by MPC treatment.

Stem Cell–Induced Neovascularization

We hypothesized that the mechanism for improvement in ventricular function in response to MPC transplantation is partially due to neovascularization. MPC-treated animals demonstrated a significant increase in vascular density compared with animals that received saline (Figure 4). This generation of new coronary vessels after ischemic injury is very important clinically, as it leads to increased blood flow to the infarct and BZ and consequently spares ischemia-threatened myocytes from apoptosis, leading to improved ventricular function. The neovascularization is probably related to an increase in both angiogenesis and vasculogenesis. Previously, we reported that vasculogenesis as evidenced by endothelial differentiation from MPCs did contribute to the increased vascular density, although only 3% of the engrafted MPCs differentiated into endothelial cells. In our present study, we observed insignificant endothelial differentiation of transplanted MPCs 4 weeks after cell transplantation. Thus, it seems that the endothelial differentiation from MPCs has a minimal effect on vasculogenesis. However, it is possible that MPC transplantation results in recruitment of endogenous cardiac or bone marrow endothelial progenitor cells that leads to vasculogenesis and contributes to the increased vascular density (Figure 4B). In addition, it has been recently demonstrated that transplantation of cardiac progenitor cells induces neovascularization primarily through vasculogenesis. Data from the present study demonstrate that MPCs secrete a significant level of VEGF under normoxic conditions, which was further increased in response to hypoxia. It has been previously reported that VEGF secretion by MSCs is a potent angiogenic factor that promotes neovascularization as well as inhibits apoptosis. Taken together, these data demonstrate that VEGF plays an important role in myocardial protection that is associated with MPC transplantation.

In summary, the present study demonstrates that transcoronary artery injection of MPCs in a porcine model of ischemia/reperfusion resulted in improvement of myocardial contractile function, reduction of BZ wall stress, limitation of scar size expansion, and balance of myocardial energy delivery and demand. Because the engraftment rate was low and myogenic differentiation was even lower, the beneficial effects are most likely related to the trophic effects of MPCs on the host myocardium, which include promotion of angiogenesis, maintenance of mitochondrial integrity, and inhibition of apoptosis of ischemia-threatened and overstretched myocytes in the BZ myocardium.

Acknowledgments

Both MPCs and Microsyringe infusion catheters (from Mercator MedSystems), were gifts kindly provided by Athysis, Inc. The rat neonatal cardiomyocytes were kindly provided by John Fassett.

Sources of Funding

This work was supported by US Public Health Service grants HL50470, HL 67828, and HL95077. X.W. was supported by American Heart Association grant-in-aid No. 0750160Z. M.N.J. was supported by American Heart Association Greater Midwest Predoctoral Award No. 081001SZ.

Disclosures

None.

References


11. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, Noiceux N, Zhang L, Pratt RE, Ingwall JS, Dzau VJ. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med. 2005;11:367–368.


13. Mirotou M, Zhang Z, Deb A, Zhang L, Gnecchi M, Noiceux N, Mu H, Pachori A, Dzau V. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc Natl Acad Sci U S A. 2007;104:1643–1648.


Stem Cells for Myocardial Repair With Use of a Transarterial Catheter
Xiaohong Wang, Mohammad Nurulqadr Jameel, Qinglu Li, Abdul Mansoor, Xiong Qiang, Cory Swingen, Carmelo Panetta and Jianyi Zhang

Circulation. 2009;120:S238-S246
doi: 10.1161/CIRCULATIONAHA.109.885236

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2009 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/120/11_suppl_1/S238

Data Supplement (unedited) at:
http://circ.ahajournals.org/content/suppl/2009/09/16/120.11_suppl_1.S238.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/
SUPPLEMENTAL MATERIAL

SUPPLEMENTAL METHODS

Cell Culture

Bone marrow derived Multipotent Progenitor Cells (MPCs) were provided from Athysis Inc. The MPCs were expanded from one of the established swMAPC (swine multipotent adult progenitor cell) lines generated in the laboratories of Drs. Verfaille and Zhang. MPCs were transduced with a Lac-Z Retrovirus (RV) supernatant (Lac-Z RV supernatants were generated by co-transfection of pVSV-G retroviral vector (BD Biosciences) and pCL-MFG-LacZ RV packaging vector (Imgenex) using the calcium phosphate method (BD Bioscience, K2051-1) in GP-293 cell line (BD Bioscience). Following transduction with a Lac-Z retrovirus at Athersys Inc., re-evaluation of the cells indicated that the level of Oct3a was significantly lower than in the parent population, and that the cells expressed CD44 and MHC-class I. Cells were maintained for extensive population doublings (>100) following gene marking and large scale expansion (data not shown), and were cytogenetically normal. Cells were assayed for in vitro differentiation response by quantitative PCR, with induction of lineage specific markers compared to non differentiated controls. The robustness of differentiation to hepatocyte and neuroectoderm-like cells was reduced in Lac-Z transduced cells, which expressed low Oct3a transcript levels compared with the parent cells that expressed...
high levels of Oct3a. These MPCs have previously been shown to maintain multi-potent differentiation potentials.

The transduced swine cells were expanded using methods developed for clinical scale production of human Multistem™. The detailed cell culture methods have been previously described. Briefly, cells were cultured in 60% DMEM-LG / 40% MCDB-201 supplemented with 1x ITS, 0.5x LA-BSA, 0.1mM L-ascorbic acid 2-phosphate, 100U penicillin and 1,000U streptomycin, 50 nM dexamethasone and 2% pre-screened FBS with 10 ng/ml each human PDGF-BB and human EGF and passaged every 2 to 3 days through removal of the growth media and addition of 5 ml 0.25% trypsin per T150 flask.

MPCs were harvested, centrifuged and resuspended at 10 million cells / 1 ml cryo preservation solution that consists of 70% growth media, 20% FBS, and 10% DMSO in 1 mL cryovials. Cells were frozen at ~1°C per minute to ~80°C and transferred into liquid nitrogen for long-term storage until of implantation. To thaw MPCs prior to grafting, basal media (expansion media without PDGF-BB, EGF, FBS, and penicillin/streptomycin) was pre-warmed to 37°C, and 9 ml of the warmed media was placed into a 15 ml conical centrifuge tube. Vials of frozen MPCs were thawed in a 37°C water bath for approximately one minute, after which cells were transferred to the pre-warmed medium. The cell number was counted to reach 50 million by hematocytometer and trypan blue was used to check cell viability during the counting. MPCs were washed by 2x PBS and spun down at 400g for 5 minutes and resuspended in 2 ml saline. A small fraction of cells was replated in a T-150 flask to check the cell
viability and percentage of Lac-z positive cells. Cells used for transplantation were >80% viable.

MPCs conditioned medium in the subsequent experiments was harvested 24 h after culture. As a control, a portion of the medium was incubated for 24 h without MPCs.

**Magnetic Resonance Imaging Methods**

Animals were examined at baseline, 1 week post infarction and then 4 weeks with MRI. MRI was performed on a 1.5 Tesla clinical scanner (Siemens Sontata, Siemens Medical Systems, Islen NJ) using a phased-array 4-channel surface coil and ECG gating. Animals were anesthetized with 1% isoflurane and positioned in a supine position within the scanner. The protocol consisted of: 1) localizing scouts to identify the long- and short-axis of the heart, 2) short- and long-axis cine for the measurement of global cardiac function, and 3) delayed contrast-enhancement for the assessment of scar size. Steady-state free precession “True-FISP” cine imaging used the following MR parameters: TR = 3.1 ms, TE = 1.6 ms, flip angle = 79°, matrix size = 256 x 120, field of view = 340 mm x 265 mm, slice thickness = 6 mm (4 mm gap between slices) and 16-20 phases were acquired across the cardiac cycle. Global function and regional wall thickness data were computed from the short-axis cine images using MASS (Medis Medical Imaging Systems, Leiden, The Netherlands) for the manual segmentation of the endocardial and epicardial surfaces at both end-diastole (ED) and end-systole (ED) from base to apex. Short-axis turboFLASH imaging, from base to apex, used TR = 16
ms, TE = 4 ms, TI ~ 220 ms, flip angle = 30°, matrix size = 256 x 148, field of view = 320 mm x 185 mm, slice thickness = 6 mm (0 mm gap between slices) and two signal averages. The appropriate inversion time (TI) was chosen to adequately null the signal intensity (SI) of normal myocardium. Infarct size was calculated from the delayed contrast-enhanced images using MASS to manually segment regions of non-viable tissue. Infarct size was calculated as the ratio of the total scar area to the total LV area.

**Spatially localized $^{31}$P-MR spectroscopy technique**

Magnetic field shimming to improve the magnetic field homogeneity of the heart was achieved by the “auto-shim” scheme (Varian Assoc. Inc., CA). Spatially localized $^{31}$P NMR spectroscopy was performed using the RAPP-ISIS/FSW method $^{3-6}$, which is the rotating-frame experiment using adiabatic plane-rotation pulses for phase modulation (RAPP)-imaging-selected in vivo spectroscopy (ISIS)/Fourier series window (FSW) method. Detailed experiments documenting voxel profiles, voxel volumes and spatial resolution attained by this method have been published previously. In this application of RAPP-ISIS/FSW, the signal origin was first restricted to a 12*12 mm two-dimensional column perpendicular to the LV wall. The signal was later localized into three well resolved and five partially resolved layers along the column and hence, across the LV wall. Localization along the column was based on B$_1$ phase encoding and employed a 9-term Fourier series window as previously describe $^{3-6}$. The phase encoded data were used to generate a voxel or a "window" that can be shifted arbitrarily by post data acquisition processing along the phase encode direction (in this case perpendicular to
the surface coil and thus the heart wall); consequently, voxels were generated at different distances or "depths" from the outer LV wall. However, we normally present five voxels centered about 45°, 60°, 90°, 120°, and 135° phase angles as previously described. There is absolutely no overlap between the 135° voxel (corresponding to the subepicardium) and the 45° voxel (corresponding to the subendocardium). Whole wall spectra were obtained with the image-selected in vivo (ISIS) technique, defining a column 12*12 mm² perpendicular to the heart wall. The calibration of spectroscopic parameters was facilitated by placing a polyethylene capillary filled with 15 µl of 3 M/L phosphonoacetic acid into the inner diameter of the surface coil. This phosphonoacetic acid standard was used only for calculating the 90 degree pulse length of the RAPP-ISIS method. The position of the voxels relative to the coil was set according to the B₁ strength at the coil center which was experimentally determined in each case by measuring the 90° pulse length for the phosphonoacetic acid standard contained in the reference capillary at the coil center. NMR data acquisition was gated to the cardiac and respiratory cycles using the cardiac cycle as the master clock to drive both the respirator and the spectrometer as previously described. The surface coil was constructed from a single turn copper wire 25 mm in diameter with each side of the coil leads soldered to a 33 pF capacitor. Complete transmural data sets were obtained in 10-minute time blocks using a repetition time of 6-7 seconds to allow for full relaxation for ATP and inorganic phosphate (Pi) and approximately 95% relaxation of the PCr resonance. The ratios of PCr to ATP (PCr/ATP) were calculated for each transmurally differentiated spectra set as previously described. All resonance intensities were quantified using integration routines provided by the SISCO software.
**1H- NMR spectroscopy technique**

1H NMR methods have been previously reported in detail \(^3\) \(^7\). In brief, radiofrequency (RF) transmission and signal detection were performed with the dually tuned 28 mm diameter surface coil. A single-pulse-collection sequence with a frequency selective Gaussian excitation pulse (1ms) was used to selectively excite the N-δ proton resonance signal of the proximal histidine in deoxymyoglobin (Mb- δ). This technique provided sufficient water suppression due to the large chemical shift difference between water and Mb- δ (>14 kHz). The NMR signal was optimized by adjusting the RF pulse power using the water signal as a reference. A short repetition time (TR = 25 ms) was used due to the short T₁ of Mb- δ. Each spectrum was acquired in 5 min (10,000 FIDs). Although the short T₁ of Mb- δ and fast acquisition prevent gating to the cardiac cycle, the signal loss due to motion is negligible compared to the inherently broad line width of the Mb- δ peak.

**Surgical preparation for open chest MR spectroscopy study**

Detailed surgical preparations for MRS study are published previously \(^2\) \(^6\) \(^8\). Briefly, animals were anesthetized with pentobarbital (30 mg/kg followed by a 4 mg/kg/hr iv), intubated and ventilated with a respirator and supplemental oxygen. Arterial blood
gases were maintained within the physiologic range by adjustments of the ventilator settings and oxygen flow. 3.0 mm OD heparin-filled polyvinyl chloride catheters were inserted into the ascending aorta (Ao) and inferior vena cava (IV). A sternotomy was performed, and the heart was suspended in a pericardial cradle. A third heparin-filled catheter was introduced into the LV through the apical dimple and secured with a purse string suture. A 25 mm diameter NMR surface coil was sutured onto the anterior wall of the LV adjacent to the infarct region. The pericardial cradle was then released, and the heart was allowed to assume its normal position in the chest. The surface coil leads were connected to a balanced-tuned external circuit and the animals positioned within the magnet. Hearts with post infarction LV remodeling are very sensitive to alterations of loading conditions of the LV, and that subtle differences in LVEDP or LVSP could affect myocardial contractile performance measurements. In order to compensate for insensible fluid loss in the open chest studies, we routinely administer saline at rate of 1 ml/min i.v. during the entire experimental data acquisition. Ventilation rate, volume and inspired oxygen content were adjusted to maintain physiologic values for arterial PO$_2$, PCO$_2$ and pH. Aortic and LV pressures were monitored continuously throughout the study. Hemodynamic measurements were acquired simultaneously with the $^1$H - and $^{31}$P- MR spectra.
**SUPPLEMENTAL TABLES**

**Supplementary Table 1. Anatomic Data obtained 4 weeks after MI**

<table>
<thead>
<tr>
<th></th>
<th>BW (kg)</th>
<th>LVW (g)</th>
<th>RVW (g)</th>
<th>LV/BW (g/kg)</th>
<th>RV/BW (g/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MI (n=6)</td>
<td>33±5</td>
<td>97±13</td>
<td>33±8</td>
<td>2.96±0.24</td>
<td>1.00±0.15</td>
</tr>
<tr>
<td>MI + Cell (n=6)</td>
<td>32±6</td>
<td>98±23</td>
<td>34±6</td>
<td>3.01±0.27</td>
<td>1.06±0.12</td>
</tr>
</tbody>
</table>

Values are mean±SD; MI, myocardial infarction; n, number of pigs; BW, Body weight; LVW, Left ventricular weight; RVW, Right ventricular weight.
### Supplementary Table 2. Hemodynamic data obtained 4 weeks after MI

<table>
<thead>
<tr>
<th></th>
<th>HR (beats/min)</th>
<th>Ao-S (mmHg)</th>
<th>Ao-D (mmHg)</th>
<th>Mean AoP (mmHg)</th>
<th>LVSP (mmHg)</th>
<th>LVEDP (mmHg)</th>
<th>RPP x 10³ (mmHg.min⁻¹)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MI</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n=6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>73±10</td>
<td>93±10</td>
<td>51±10</td>
<td>65±6</td>
<td>99±13</td>
<td>5±1</td>
<td>7.14±1.24</td>
</tr>
<tr>
<td>DB+DP</td>
<td>135±26</td>
<td>124±19</td>
<td>54±14</td>
<td>77±11</td>
<td>151±18</td>
<td>7.5±2.9</td>
<td>20.51±5.15</td>
</tr>
<tr>
<td>p-value</td>
<td>&lt;0.001</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>0.009</td>
<td>NS</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>within MI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MI + Cell</strong></td>
<td>(n=6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>100±28</td>
<td>95±18</td>
<td>63±21</td>
<td>74±19</td>
<td>108±26</td>
<td>5±1</td>
<td>11.02±5.12</td>
</tr>
<tr>
<td>DB+DP</td>
<td>148±23</td>
<td>110±29</td>
<td>63±16</td>
<td>79±19</td>
<td>148±28</td>
<td>6.7±2.6</td>
<td>21.58±3.87</td>
</tr>
<tr>
<td>p-value</td>
<td>&lt;0.001</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>0.013</td>
<td>NS</td>
<td>0.001</td>
</tr>
<tr>
<td>within MI+Cell</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Values are mean±SD; n, number of pigs; MI, myocardial infarction; DbDp, Dobutamine and Dopamine (each 20µg/kg/min intravenous); HR, heart rate; Ao-S, aortic systolic pressure; Ao-D, aortic diastolic pressure; LVSP, left ventricular systolic pressure; LVEDP, left ventricular end diastolic pressure; RPP, rate pressure product (HR x LVSP); NS, Not significant; Repeated Measures ANOVA p value is not significant for the effect of cell treatment with inotropic stimulation (p=0.353). Pair-wise comparisons within groups are listed in the table.
SUPPLEMENTAL REFERENCES


